Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns

Richard L. Wahl; George Sgouros; Amir Iravani; Heather Jacene; Daniel Pryma; Babak Saboury; Jacek Capala; Stephen A. Graves

doi:10.2967/jnumed.121.262751

Research ArticleClinical (Radiobiology/Dosimetry/Safety)

Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns

Richard L. Wahl, George Sgouros, Amir Iravani, Heather Jacene, Daniel Pryma, Babak Saboury, Jacek Capala and Stephen A. Graves

Journal of Nuclear Medicine December 2021, 62 (Supplement 3) 23S-35S; DOI: https://doi.org/10.2967/jnumed.121.262751

Richard L. Wahl

1Mallinckrodt Institute of Radiology, Washington University, St. Louis, Missouri

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

George Sgouros

2Department of Radiology, Johns Hopkins University, Baltimore, Maryland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Amir Iravani

1Mallinckrodt Institute of Radiology, Washington University, St. Louis, Missouri

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Heather Jacene

3Dana-Farber Cancer Institute, Boston, Massachusetts

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Daniel Pryma

4Penn Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Babak Saboury

5National Institutes of Health, Bethesda, Maryland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Jacek Capala

5National Institutes of Health, Bethesda, Maryland

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Stephen A. Graves

6University of Iowa, Iowa City, Iowa

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Article
Figures & Data
Info & Metrics
PDF

Article Information

vol. 62 no. Supplement 3 23S-35S

DOI

https://doi.org/10.2967/jnumed.121.262751

PubMed

34857619

Published By

Society of Nuclear Medicine

Print ISSN

0161-5505

Online ISSN

2159-662X

History

Received for publication August 24, 2021
Revision received October 15, 2021
Published online December 2, 2021.

Author Information

Statistics from Altmetric.com

Cited By...

51 Citations
Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

Fibroblast Activation Protein-Targeted Radioligand Therapy with 177Lu-EB-FAPI for Metastatic Radioiodine-Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study

Hao Fu, Jingxiong Huang, Tianzhi Zhao, Hongjian Wang, Yuhang Chen, Weizhi Xu, Yizhen Pang, Wei Guo, Long Sun, Hua Wu, Pengfei Xu, Bishan Su, Jingjing Zhang, Xiaoyuan Chen, Haojun Chen

Clinical Cancer Research 2023 29 23
Developments in 177Lu-based radiopharmaceutical therapy and dosimetry

Siju C. George, E. James Jebaseelan Samuel

Frontiers in Chemistry 2023 11
Dosimetry in Radiopharmaceutical Therapy

Joe O’Donoghue, Pat Zanzonico, John Humm, Adam Kesner

Journal of Nuclear Medicine 2022 63 10
Personalized Dosimetry in Targeted Radiation Therapy: A Look to Methods, Tools and Critical Aspects

Rachele Danieli, Alessia Milano, Salvatore Gallo, Ivan Veronese, Alessandro Lascialfari, Luca Indovina, Francesca Botta, Mahila Ferrari, Alessandro Cicchetti, Davide Raspanti, Marta Cremonesi

Journal of Personalized Medicine 2022 12 2
First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX–Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma

Michael S. Hofman, Ben Tran, Darren R. Feldman, Anna Pokorska-Bocci, Solen Pichereau, Jonathan Wessen, Mohammad B. Haskali, Richard B. Sparks, Olena Vlasyuk, Ivana Galetic

Journal of Nuclear Medicine 2024 65 5
The Impact of Radiopharmaceutical Therapy on Renal Function

Eunkyung Angela Park, Stephen A. Graves, Yusuf Menda

Seminars in Nuclear Medicine 2022 52 4
Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment

Caroline P. Kerr, Joseph J. Grudzinski, Thanh Phuong Nguyen, Reinier Hernandez, Jamey P. Weichert, Zachary S. Morris

Pharmaceutics 2022 15 1
How Can Radiopharmaceutical Therapies Reach Their Full Potential? Improving Dose Reporting and Phase I Clinical Trial Design

Ana P. Kiess, Joseph O'Donoghue, Carlos Uribe, Lisa Bodei, Robert F. Hobbs, Jacob Hesterman, Adam L. Kesner, George Sgouros, Tom Bäck, Manuel Bardies, Alessandro Bartolini, Sören Bentzen, Peter Bernhardt, Ingrid Bloise, Lisa Bodei, Wesley Bolch, Patrik Brodin, Julia Brosch-Lenz, Jacek Capala, Carlo Chiesa, Patricia E. Cole, Marta Cremonesi, Emmanuel Deshayes, Yuni Dewaraja, Roberto Formento-Cavaier, Gerhard Glatting, Harwig Hennekes, Jacob Hesterman, Rob Hobbs, Vicki Jardine, Jessica Jensen, Adam Kesner, Ana P. Kiess, Mark W. Konijnenberg, Clemens Kratochwil, Phillip H. Kuo, Roberto Maass-Moreno, Michael Morris, Quyen Nguyen, Joseph O'Donoghue, Stig Palm, Neeta Pandit-Taskar, Laurens Raes, Hendrik Rathke, Babak Saboury, Nicola Salem, Lore Santoro, Oliver Sartor, Mike Sathekge, George Sgouros, Eileen Sneeden, Lidia Strigari, Scott Tagawa, Carlos Uribe, Amanda Walker, Wolfgang Weber, Fred Wilson, Tahir Yusufaly, Sabine Zitzmann-Kolbe

Journal of Clinical Oncology 2024 42 15
A Primer on Radiopharmaceutical Therapy

Kilian E. Salerno, Soumyajit Roy, Cathy Ribaudo, Teresa Fisher, Ravi B. Patel, Esther Mena, Freddy E. Escorcia

International Journal of Radiation Oncology*Biology*Physics 2023 115 1
Towards the Magic Radioactive Bullet: Improving Targeted Radionuclide Therapy by Reducing the Renal Retention of Radioligands

Kim E. de Roode, Lieke Joosten, Martin Behe

Pharmaceuticals 2024 17 2

Article usage

Article usage: December 2021 to April 2025

	Full	Pdf
Dec 2021	205	170
Jan 2022	158	75
Feb 2022	155	85
Mar 2022	136	66
Apr 2022	137	62
May 2022	109	66
Jun 2022	123	56
Jul 2022	111	58
Aug 2022	95	73
Sep 2022	135	62
Oct 2022	128	64
Nov 2022	127	69
Dec 2022	99	35
Jan 2023	104	55
Feb 2023	159	65
Mar 2023	172	80
Apr 2023	140	66
May 2023	156	88
Jun 2023	146	73
Jul 2023	132	66
Aug 2023	163	80
Sep 2023	166	77
Oct 2023	173	84
Nov 2023	139	61
Dec 2023	160	74
Jan 2024	281	92
Feb 2024	201	93
Mar 2024	228	114
Apr 2024	13876	103
May 2024	303	121
Jun 2024	237	81
Jul 2024	390	144
Aug 2024	313	103
Sep 2024	325	116
Oct 2024	296	103
Nov 2024	456	132
Dec 2024	397	97
Jan 2025	475	131
Feb 2025	452	101
Mar 2025	471	115
Apr 2025	796	175

PreviousNext

In this issue

Journal of Nuclear Medicine

Vol. 62, Issue Supplement 3

December 1, 2021

Table of Contents
Table of Contents (PDF)
About the Cover
Index by author
Complete Issue (PDF)

Download PDF

Article Alerts

User Name *

Password *

Email *

Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns

Message Subject (Your Name) has sent you a message from Journal of Nuclear Medicine

Message Body (Your Name) thought you would like to see the Journal of Nuclear Medicine web site.

Your Personal Message

Citation Tools

Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns

Richard L. Wahl, George Sgouros, Amir Iravani, Heather Jacene, Daniel Pryma, Babak Saboury, Jacek Capala, Stephen A. Graves

Journal of Nuclear Medicine Dec 2021, 62 (Supplement 3) 23S-35S; DOI: 10.2967/jnumed.121.262751

Citation Manager Formats

BibTeX
Bookends
EasyBib
EndNote (tagged)
EndNote 8 (xml)
Medlars
Mendeley
Papers
RefWorks Tagged
Ref Manager
RIS
Zotero

Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns

Richard L. Wahl, George Sgouros, Amir Iravani, Heather Jacene, Daniel Pryma, Babak Saboury, Jacek Capala, Stephen A. Graves

Journal of Nuclear Medicine Dec 2021, 62 (Supplement 3) 23S-35S; DOI: 10.2967/jnumed.121.262751

Share This Article:

Tweet Widget
Facebook Like
Google Plus One

Bookmark this article

User Name *

Password *

Remember my user name & password.

Jump to section

Article
Figures & Data
Info & Metrics
PDF

No related articles found.

PubMed
Google Scholar

Cited By...

Theranostic GPA33-Pretargeted Radioimmunotherapy of Human Colorectal Carcinoma with a Bivalent 177Lu-Labeled Radiohapten
Design of a Fibroblast Activation Protein-Targeted Radiopharmaceutical Therapy with High Tumor-to-Healthy-Tissue Ratios
Assessing Response to PSMA Radiopharmaceutical Therapies with Single SPECT Imaging at 24 Hours After Injection
Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers
First-in-Human Safety, Imaging, and Dosimetry of a Carbonic Anhydrase IX-Targeting Peptide, [68Ga]Ga-DPI-4452, in Patients with Clear Cell Renal Cell Carcinoma
Rethinking Dosimetry: The Perils of Extrapolated External-Beam Radiotherapy Constraints to Radionuclide Therapy
Quality Assurance Considerations in Radiopharmaceutical Therapy Dosimetry Using PLANETDose: An International Atomic Energy Agency Study
Dosimetry in Radiopharmaceutical Therapy
Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns
Radiopharmaceutical Dosimetry for Cancer Therapy: From Theory to Practice

Google Scholar

Main menu

User menu

Search

Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns

Article Information

Author Information

Statistics from Altmetric.com

Cited By...

Article usage

Article usage: December 2021 to April 2025

In this issue

Citation Manager Formats

Related Articles

Cited By...

More in this TOC Section

Similar Articles